All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 12 October 2018, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to STRO-001, a first-in-class antibody-drug conjugate (ADC), for the treatment of patients with multiple myeloma (MM).1
CD74, a transmembrane glycoprotein involved in the formation and transport of MHC proteins, has been reported to have a high expression in up to 90% of B-cell malignancies, including MM, with minimal expression in normal tissues. STRO-001 is a novel ADC targeting CD74 glycoprotein. Preclinical data have shown that STRO-001 demonstrates a potent cytotoxicity in MM cell lines and reduces tumor burden in MM xenograft models, including significant prolongation of survival in the MM.1S model.2
A first-in-human phase I, open-label, multicenter, dose-escalation study (NCT03424603) evaluating the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies including MM and non-Hodgkin lymphoma who are refractory to, or intolerant of all established therapy known to provide clinical benefit for their conditions is currently ongoing.
Subscribe to get the best content related to multiple myeloma delivered to your inbox